Varicella Zoster

Most pediatric transplant recipients who received live-attenuated viral vaccines after transplant developed protective antibodies that persisted for up to a year after vaccination with no significant safety events, researchers found.

New data showed that the live attenuated varicella-zoster vaccine was safe and provided short-term effectiveness in patients receiving TNF inhibitors. A report on the data was the top story in rheumatology last week.

The live attenuated varicella-zoster vaccine is safe and provides “reasonable short-term” effectiveness in patients receiving TNF inhibitors for a variety of indications, according to data published in the Annals of Internal Medicine.